» Articles » PMID: 37579081

Enteral Tube Feeding for Amyotrophic Lateral Sclerosis/motor Neuron Disease

Overview
Publisher Wiley
Date 2023 Aug 14
PMID 37579081
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Maintaining adequate nutrition is critical for people with amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND). Enteral tube feeding is offered to people experiencing difficulty swallowing (dysphagia) to prevent weight loss and aspiration pneumonia. Among the types of enteral tube feeding, percutaneous endoscopic gastrostomy (PEG) is the typical procedure offered to people with ALS and will be mainly discussed here.

Objectives: To examine the effectiveness of percutaneous endoscopic gastrostomy or other enteral tube feeding in people with ALS, compared to oral feeds without enteral tube feeding on: 1. survival; 2. nutritional status; 3. quality of life. To examine the incidence of minor and major complications of percutaneous endoscopic gastrostomy (PEG) and other enteral tube feeding procedures in people with ALS.

Search Methods: On 3 January 2020 and 6 February 2021, we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE. Embase, ClinicalTrials.gov and WHO ICTRP. We screened the results to identify randomized controlled studies on enteral tube feeding in ALS. We reviewed all references from the search in published articles to identify any additional references.

Selection Criteria: We included randomized controlled trials (RCTs), quasi-RCTs, and cross-over trials evaluating the effectiveness and complications of PEG or other enteral tube feeding placement in ALS.

Data Collection And Analysis: We used standard methodological procedures expected by Cochrane.

Main Results: We found no RCTs or quasi-RCTs comparing the effectiveness of enteral tube feeding versus oral feeds without enteral tube feeding.

Authors' Conclusions: There are no RCTs or quasi-RCTs to indicate whether enteral tube feeding is effective compared to continuation of oral feeding for any of the outcome measures. Such RCTs are very unlikely to be performed for ethical reasons. RCTs evaluating the effect of different enteral tube insertion techniques and timings of tube placement on survival and quality of life of people with ALS dysphagia are feasible and warranted.

Citing Articles

The Application and Mechanism Analysis of Enteral Nutrition in Clinical Management of Chronic Diseases.

Li Q, Wang J Nutrients. 2025; 17(3).

PMID: 39940308 PMC: 11820659. DOI: 10.3390/nu17030450.


Narrative review of diagnosis, management and treatment of dysphagia and sialorrhea in amyotrophic lateral sclerosis.

Bjelica B, Petri S J Neurol. 2024; 271(10):6508-6513.

PMID: 39207520 PMC: 11447084. DOI: 10.1007/s00415-024-12657-x.


Practical recommendations for swallowing and speaking during NIV in people with neuromuscular disorders.

Andersen T, Bolton L, Toussaint M Acta Myol. 2024; 43(2):62-70.

PMID: 39082323 PMC: 11305350. DOI: 10.36185/2532-1900-417.


Timing and impact of percutaneous endoscopic gastrostomy insertion in patients with amyotrophic lateral sclerosis: a comprehensive analysis.

Son B, Lee J, Ryu S, Park Y, Kim S Sci Rep. 2024; 14(1):7103.

PMID: 38531942 PMC: 10965990. DOI: 10.1038/s41598-024-56752-5.


Supporting people with Motor Neuron Disease (MND) to make decisions about gastrostomy feeding tube placement: a survey of UK healthcare professionals' practice and beliefs.

White S, OCathain A, Halliday V, Bradburn M, McDermott C Amyotroph Lateral Scler Frontotemporal Degener. 2024; 25(3-4):290-298.

PMID: 38337170 PMC: 11262427. DOI: 10.1080/21678421.2024.2314061.

References
1.
Oliver D, Turner M . Some difficult decisions in ALS/MND. Amyotroph Lateral Scler. 2010; 11(4):339-43. PMC: 3182548. DOI: 10.3109/17482968.2010.487532. View

2.
Talman P, Duong T, Vucic S, Mathers S, Venkatesh S, Henderson R . Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. BMJ Open. 2016; 6(9):e012054. PMC: 5051496. DOI: 10.1136/bmjopen-2016-012054. View

3.
Andersen P, Kuzma-Kozakiewicz M, Keller J, Aho-Oezhan H, Ciecwierska K, Szejko N . Therapeutic decisions in ALS patients: cross-cultural differences and clinical implications. J Neurol. 2018; 265(7):1600-1606. DOI: 10.1007/s00415-018-8861-4. View

4.
Klavzar P, Koritnik B, Leonardis L, Groselj L, Kirbis M, Ristic Kovacic S . Improvements in the multidisciplinary care are beneficial for survival in amyotrophic lateral sclerosis (ALS): experience from a tertiary ALS center. Amyotroph Lateral Scler Frontotemporal Degener. 2020; 21(3-4):203-208. DOI: 10.1080/21678421.2020.1746809. View

5.
Vergonjeanne M, Fayemendy P, Marin B, Penoty M, Lautrette G, Sourisseau H . Predictive factors for gastrostomy at time of diagnosis and impact on survival in patients with amyotrophic lateral sclerosis. Clin Nutr. 2020; 39(10):3112-3118. DOI: 10.1016/j.clnu.2020.01.018. View